Status:
UNKNOWN
Vit D3 and Omega 3 in Chemo Induced Neuropathy
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Cancer
Neuropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether administration of mammalian Omega 3 FA(fatty acid) with Vitamin D3 supplements would lower or prevent the risk of neuropathy due to chemotherapy.
Detailed Description
The primary objective of this study is to evaluate the impact of mammalian oil Omega 3 FA with Vitamin D3 supplementation on resolution or prevention of Taxanes or Platinum induced peripheral neuropat...
Eligibility Criteria
Inclusion
- Will be receiving chemotherapy(Platinums and/or Taxanes) in the following 2 weeks.
- Histologically confirmed diagnosis of cancer
- ECOG 0 to 2
Exclusion
- Prior chemotherapy treatment
- Pre-existing peripheral PN due to DM,HIV, alcohol abuse, thyroid dysfunction and hereditary PN associated disorders.
- Taking any nutritional supplement( fish oil, vitamins and minerals) at least there months before enrollment.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2016
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT02294149
Start Date
January 1 2015
End Date
November 1 2016
Last Update
April 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill university health center, Royal Victoria hospital
Montreal, Quebec, Canada, h3a 1a1